You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bi-Specific T-Cell Engager

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)

Not yet recruiting
  • Malignant Glioma
  • Glioblastoma
  • hEGFRvIII-CD3 (BRiTE)
  • Activated Cell Therapy
  • Durham, North Carolina
    Duke University Medical Center
Jun 24, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Small Cell Lung Carcinoma, Neuroendocrine Tumors Trial (BI 764532)

Not yet recruiting
  • Small Cell Lung Carcinoma
  • Neuroendocrine Neoplasms
  • BI 764532
  • (no location specified)
May 22, 2023

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/79b T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR PSMA/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Apr 17, 2022

    B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

    Recruiting
    • B Cell Non-Hodgkin's Lymphoma
    • CD19/CD20-directed CAR-T cells
    • Duarte, California
      City of Hope Medical Center
    Aug 10, 2022

    High-risk MDS, Acute Myelogenous Leukemia, Systemic Mastocytosis Trial in Minneapolis, Madison (GTB-3550 TriKE® Phase I,

    Terminated
    • High-risk Myelodysplastic Syndromes
    • +3 more
    • GTB-3550 TriKE® Phase I
    • GTB-3550 TriKE® Phase II
    • Minneapolis, Minnesota
    • +1 more
    Mar 21, 2022

    B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

    Recruiting
    • B Cell Malignancies
    • Universal CD19-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 8, 2023

    CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

    Active, not recruiting
    • Central Nervous System Tumor, Pediatric
    • +8 more
    • EGFR806-specific chimeric antigen receptor (CAR) T cell
    • Seattle, Washington
      Seattle Children's Hospital
    Jan 18, 2023

    Hematological Malignancies, CMV Infection Trial in Belgium (CMV-specific T cells, Standard anti-viral therapy)

    Completed
    • Hematological Malignancies
    • CMV Infection
    • CMV-specific T cells
    • Standard anti-viral therapy
    • Gent, Oost-Vlaanderen, Belgium
    • +7 more
    Dec 19, 2022

    Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections Trial in Pittsburgh (Specific T- Lymphocytes)

    Not yet recruiting
    • Adenovirus
    • +2 more
    • Specific T- Lymphocytes
    • Pittsburgh, Pennsylvania
      UPMC Children's Hospital of Pittsburgh
    Sep 8, 2023

    Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

    Active, not recruiting
    • Leukemia
    • Acute Lymphoblastic Leukemia
    • gene-modified T cells targeted
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Feb 1, 2023

    High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin

    Not yet recruiting
    • High Grade B-Cell Non-Hodgkin's Lymphoma
    • +3 more
    • Anti-CD19-CAR CMV-specific T-lymphocytes
    • +9 more
    • Duarte, California
      City of Hope Medical Center
    Apr 5, 2023

    Chronic Hepatitis B Trial in Beijing (TCR-T)

    Active, not recruiting
    • Chronic Hepatitis B
    • TCR-T
    • Beijing, China
      The Fifth Medical Center of PLA General Hospital
    Jun 13, 2023

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections Trial in Cleveland (CMV specific

    Recruiting
    • Cytomegalovirus Infections
    • +2 more
    • CMV specific adoptive t-cells
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Jul 26, 2022

    CMV Infection, EBV Infection, Stem Cell Transplant Trial (Virus specific T cells)

    Not yet recruiting
    • CMV Infection
    • +2 more
    • Virus specific T cells
    • (no location specified)
    Oct 4, 2023

    Multiple Myeloma Trial in New York (drug, biological, procedure)

    Active, not recruiting
    • Multiple Myeloma
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jan 3, 2023

    CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (HER2-specific chimeric antigen receptor (CAR) T cell)

    Recruiting
    • Central Nervous System Tumor, Pediatric
    • +8 more
    • HER2-specific chimeric antigen receptor (CAR) T cell
    • Seattle, Washington
      Seattle Children's Hospital
    Dec 14, 2022